Firefly Neuroscience, Inc. (AIFF)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 69/100 (HIGH), 17.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.09% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
- Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine
- Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
- Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
- Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
- With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
- The Small Cap Showcase Highlights 8 Public Companies at Their Investor Conference Today
- Firefly Confirms Public-Private Partnership with the Department of War
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Firefly Neuroscience, Inc..
Full AIFF Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.